Trial reportCephalalgia : an international journal of headache2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
Trial report in Cephalalgia : an international journal of headache, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02438826 (A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of), which is not on this map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Efficacy and safety of CGRP monoclonal antibodies for cluster headache: a systematic review and network meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Safety and efficacy of calcitonin gene-related peptide antagonists for cluster headache: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment.The journal of headache and pain · 2025Pooled it
- Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.Cephalalgia : an international journal of headache · 2019Pooled it
- Safety and efficacy of occipital nerve stimulation as treatment of chronic cluster headache: an investigator-initiated, double-blind, randomized, placebo-controlled study.The journal of headache and pain · 2026Trial
- Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache.The journal of headache and pain · 2022Trial
- Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.Headache · 2022Trial
- Tear Fluid Calcitonin Gene-Related Peptide Levels Are Elevated in Glycerol Trinitrate-Induced Cluster Headache Attacks: Results From an Exploratory Study.European journal of neurology · 2026Article
- Can atogepant be a preventive treatment for cluster headache?-Insights from a case series.Headache · 2026Article
- Hallmarks of primary headache: part 3 - cluster headache.The journal of headache and pain · 2025Review
- Distinct Alterations of Inflammatory Biomarkers in Cluster Headache: A Case Control Study.Annals of neurology · 2025Article
- 15. Cluster Headache.Pain practice : the official journal of World Institute of Pain · 2025Review
- Cluster Headache in Children: Current Status, Diagnostic and Treatment Challenges and Future.Current pain and headache reports · 2025Review
- Unraveling the relationship between inflammation and cluster headache.Frontiers in neurology · 2025Review
- Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group.Frontiers in neurology · 2025Article
- Cluster Headache and Hypoxia: Breathing New Life into an Old Theory, with Novel Implications.Neurology international · 2024Review
- Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Observational
- Acute and preventive medical treatment of cluster headache in Taiwan: A narrative review.Journal of the Chinese Medical Association : JCMA · 2024Review
- Galcanezumab add-on in refractory cluster headache. A case series.Pain management · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report efficacy and safety of galcanezumab in adults with chronic cluster headache.
backgroundGalcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity.
methodsThis study comprised a prospective baseline period, a 12-week double-blind, placebo-controlled treatment period, and a 52-week open-label period. Up to six protocol-specified concomitant preventive medications were allowed if patients were on a stable dose for 2 months prior to the prospective baseline period. Patients were randomized 1:1 to monthly subcutaneous galcanezumab (300 mg) or placebo. The primary endpoint was overall mean change from baseline in weekly attack frequency with galcanezumab compared to placebo. Key secondary endpoints were ≥50% response rate and percentage of patients meeting sustained response. Results from the double-blind treatment period are reported.
resultsA total of 237 patients were randomized and treated (120 placebo; 117 galcanezumab). At baseline, the mean age was 45 years and 63% were using ≥1 preventive drug. The primary endpoint was not met; mean change in weekly attack frequency was -4.6 placebo versus -5.4 galcanezumab (
conclusionTreatment with galcanezumab 300 mg did not achieve its primary and key secondary endpoints. This study underscores the potential distinct biology of cCH as well as the significant unmet need for safe, effective, and well-tolerated preventive treatment. The safety profile of galcanezumab in cCH is consistent with that observed in trials of episodic CH and migraine.
trial registrationNCT02438826; https://www.clinicaltrials.gov/ct2/show/NCT02438826.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.